Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jaromír Švestka"'
Psychiatry in selected countries of Central and Eastern Europe: an overview of the current situation
Autor:
István Bitter, Norman Sartorius, János Füredi, Dave Swingler, Jaromír Švestka, Ljubomir Hotujac, Marga Kocmur, Georgy Ivanov Koychev, Mihai Dumitru Gheorghe, Jan Pecenak, Janusz K. Rybakowski, Pavel Mohr, Sergey Mosolov, Marek Jarema
Publikováno v:
Acta Psychiatrica Scandinavica. 114:223-231
Fu¨redi J, Mohr P, Swingler D, Bitter I, Gheorghe MD, Hotujac L,Jarema M, Kocmur M, Koychev GI, Mosolov SN, Pecenak J,Rybakowski J, Svestka J, Sartorius N. Psychiatry in selected countriesof Central and Eastern Europe: an overview of the current sit
Autor:
Norman Sartorius, Thomas C. Baghai, David S. Baldwin, Barbara Barrett, Ursula Brand, Wolfgang Fleischhacker, Guy Goodwin, Heinz Grunze, Martin Knapp, Brian E. Leonard, Jeffrey Lieberman, Yoshibumi Nakane, Roger M. Pinder, Alan F. Schatzberg, Jaromír Švestka, Pierre Baumann, Kareem Ghalib, John C. Markowitz, Frank Padberg, Roger Pinder, Max Fink, Toshiaki Furukawa, Konstantinos N. Fountoulakis, Peter Jensen, Shigenobu Kanba, Anita Riecher-Rössler
Publikováno v:
The International Journal of Neuropsychopharmacology. 10
According to the World Health Organization, depression is one of the most debilitating disorders affecting humankind. The social and economic costs of chronic ill health resulting from untreated or inadequately treated depression are considerable and
Autor:
Eva Češková, Jaromír Švestka
Publikováno v:
Scopus-Elsevier
A double-blind eight-week study was carried out to compare the efficacy and safety of risperidone in relation to haloperidol. Sixty-two inpatients suffering from acute schizophrenic or schizoaffective psychoses diagnosed according to ICD-9 were treat
Autor:
O. Synek, Jaromír Švestka
Publikováno v:
European Neuropsychopharmacology. 10:252-253
Publikováno v:
European Neuropsychopharmacology. 13:S236
In double-blind trial the antidepressant effect of sertraline did not differ significantly from that of amitriptyline and the in-patients with depressive disorder tolerated sertraline better than amitriptyline
Publikováno v:
European Neuropsychopharmacology. 13:S291
In double-blind randomized trial olanzapine was more suitable antipsychotic for the treatment of first-episode psychoses for the greater final improvement, better reduction of negative symptoms a fewer extrapyramidal side -effects and hyperprolactine
Publikováno v:
European Neuropsychopharmacology. 6:149